Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2018 Dec 13;10(12):535.
doi: 10.3390/toxins10120535.

AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients

Malgorzata Field  1 , Andrew Splevins  2 , Philippe Picaut  3 , Marcel van der Schans  4 , Jan Langenberg  5 , Daan Noort  6 , Daniel Snyder, Keith Foster  7
Affiliations
Comparative Study

AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients

Malgorzata Field et al. Toxins (Basel). .

Erratum in

Abstract

Botulinum neurotoxin type-A (BoNT-A) blocks the release of acetylcholine from peripheral cholinergic nerve terminals and is an important option for the treatment of disorders characterised by excessive cholinergic neuronal activity. Several BoNT-A products are currently marketed, each with unique manufacturing processes, excipients, formulation, and non-interchangeable potency units. Nevertheless, the effects of all the products are mediated by the 150 kDa BoNT-A neurotoxin. We assessed the quantity and light chain (LC) activity of BoNT-A in three commercial BoNT-A products (Dysport®; Botox®; Xeomin®). We quantified 150 kDa BoNT-A by sandwich ELISA and assessed LC activity by EndoPep assay. In both assays, we assessed the results for the commercial products against recombinant 150 kDa BoNT-A. The mean 150 kDa BoNT-A content per vial measured by ELISA was 2.69 ng/500 U vial Dysport®, 0.90 ng/100 U vial Botox®, and 0.40 ng/100 U vial Xeomin®. To present clinically relevant results, we calculated the 150 kDa BoNT-A/US Food and Drug Administration (FDA)-approved dose in adult upper limb spasticity: 5.38 ng Dysport® (1000 U; 2 × 500 U vials), 3.60 ng Botox® (400 U; 4 × 100 U vials), and 1.61 ng Xeomin® (400 U; 4 × 100 U vials). EndoPep assay showed similar LC activity among BoNT-A products. Thus, greater amounts of active neurotoxin are injected with Dysport®, at FDA-approved doses, than with other products. This fact might explain the long duration of action reported across multiple indications, which benefits patients, caregivers, clinicians, and healthcare systems.

Keywords: BoNT; Dysport®, abobotulinumtoxinA; botulinum toxin; glabellar lines; spasticity.

PubMed Disclaimer

Conflict of interest statement

M.F., A.S., K.F., and P.P. are employed by Ipsen Pharma. M.v.d.S., J.L., and D.N. are employed by TNO.

Figures

Figure 1
Figure 1
Representative standard curve obtained using BoLISA® antibody pair detection of recombinant BoNT-A1.
See this image and copyright information in PMC

References

    1. Simpson D.M., Hallett M., Ashman E.J., Comella C.L., Green M.W., Gronseth G.S., Armstrong M.J., Gloss D., Potrebic S., Jankovic J., et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Neurology. 2016;86:1818–1826. doi: 10.1212/WNL.0000000000002560. - DOI - PMC - PubMed
    1. Carruthers J., Fournier N., Kerscher M., Ruiz-Avila J., Trinindade de Almeida A.R., Kaeuper G. The convergence of medicine and neurotoxins: A focus on botulinum toxin type A and its application in aesthetic medicine—A global, evidence-based botulinum toxin consensus education initiative: Part II: Incorporating botulinum toxin into aesthetic clinical practice. Dermatol. Surg. 2013;39:510–525. - PubMed
    1. Ashford S., Turner-Stokes L. Spasticity in Adults: Management Using Botulinum Toxin: National Guidelines. Royal College of Physicians of London; London, UK: 2018.
    1. Foster K.A. Overview and history of botulinum neurotoxin clinical exploitation. In: Foster K.A., editor. Clinical Applications of Botulinum Neurotoxin. Springer; New York, NY, USA: 2014. pp. 1–5.
    1. Kukreja R., Singh B.R. The botulinum toxin as a therapeutic agent: Molecular and pharmacological insights. Res. Rep. Biochem. 2015;5:173–183.

Publication types

MeSH terms